Evotec SE announced that the Company has received a US$ 18 m grant from the Bill & Melinda Gates Foundation (Seattle, WA, USA, “the foundation”) for the integrated discovery and development of a novel, first-in-class programme to accelerate progress in the area of women’s health and contraceptive technology, leveraging Evotec’s integrated R&D platform.
Evotec receives US$ 18 m grant for women's health
The project makes use of Evotec’s fully-integrated drug discovery and development platforms as well as therapeutic area expertise to take an idea from concept to nomination of a pre-clinical development candidate. To efficiently deliver safe and efficacious pre-clinical drug candidates, Evotec will use its extensive toolbox of computational tools, structural biology, therapeutic area knowledge, translational biology models, safety assessment and deep talent across the full R&D continuum.
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “We are very excited to embark on the mission of delivering a first-in-class women’s health programme to the clinic and making it globally available. This new grant from the Bill & Melinda Gates Foundation allows us to leverage Evotec’s integrated platform for the discovery and development of novel, safe and efficacious drug candidates. We are grateful for the foundation’s trust in the capabilities of our integrated platform and look forward to delivering a novel option with the potential of changing the lives of many women to the better.”
Biotech & Pharma
Eppendorf divests micro manipulation product portfolio
The globally active Eppendorf Group has divested its micro manipulation product portfolio to Calibre Scientific GmbH in Hamburg, Germany. Calibre ...
Biotech & Pharma, Research, Academia & Universities
Scientists engineer new potent antibiotic
In the constant arms race with bacteria, scientists at the Centre for Structural Systems Biology CSSB together with colleagues from the Helmholtz Institute for Pharmaceutical ...
Crown Bioscience to Acquire Indivumed’s Service Business
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the ...